3/11
12:53 pm
gmab
Genmab A/S (NASDAQ: GMAB) had its price target lowered by analysts at Truist Financial Co. from $50.00 to $45.00. They now have a "buy" rating on the stock.
Low
Report
Genmab A/S (NASDAQ: GMAB) had its price target lowered by analysts at Truist Financial Co. from $50.00 to $45.00. They now have a "buy" rating on the stock.
3/11
08:09 am
gmab
Genmab A/S (NASDAQ: GMAB) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.
Medium
Report
Genmab A/S (NASDAQ: GMAB) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.
3/10
10:21 am
gmab
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
Low
Report
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
3/10
10:13 am
gmab
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
Medium
Report
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
3/10
04:26 am
gmab
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan [Yahoo! Finance]
Medium
Report
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan [Yahoo! Finance]
2/20
08:51 am
gmab
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma [Yahoo! Finance]
Low
Report
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma [Yahoo! Finance]
2/20
08:00 am
gmab
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma
Low
Report
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma
2/18
10:37 am
gmab
Bispecific Antibody Market Expands with Over 600 Clinical Trials – New Patent Analysis Report Released [Yahoo! Finance]
Low
Report
Bispecific Antibody Market Expands with Over 600 Clinical Trials – New Patent Analysis Report Released [Yahoo! Finance]
2/14
07:41 am
gmab
Genmab A/S (NASDAQ: GMAB) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
Low
Report
Genmab A/S (NASDAQ: GMAB) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
2/14
06:48 am
gmab
Genmab A/S 2024 Q4 - Results - Earnings Call Presentation [Seeking Alpha]
Low
Report
Genmab A/S 2024 Q4 - Results - Earnings Call Presentation [Seeking Alpha]
2/13
08:06 am
gmab
Genmab A/S (NASDAQ: GMAB) was upgraded by analysts at BNP Paribas from a "strong sell" rating to a "hold" rating.
Medium
Report
Genmab A/S (NASDAQ: GMAB) was upgraded by analysts at BNP Paribas from a "strong sell" rating to a "hold" rating.
2/13
07:15 am
gmab
Genmab A/S (NASDAQ: GMAB) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $27.00 price target on the stock.
Low
Report
Genmab A/S (NASDAQ: GMAB) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $27.00 price target on the stock.
2/12
12:19 pm
gmab
Genmab Publishes 2024 Annual Report [Yahoo! Finance]
Low
Report
Genmab Publishes 2024 Annual Report [Yahoo! Finance]
2/12
11:01 am
gmab
Genmab Publishes 2024 Annual Report
Medium
Report
Genmab Publishes 2024 Annual Report
2/12
04:53 am
gmab
Lundbeck's potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA [Yahoo! Finance]
Low
Report
Lundbeck's potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA [Yahoo! Finance]
2/8
09:44 pm
gmab
Why Genmab A/S (GMAB) Is Among the Best Healthcare Stocks To Buy According to Analysts [Yahoo! Finance]
Low
Report
Why Genmab A/S (GMAB) Is Among the Best Healthcare Stocks To Buy According to Analysts [Yahoo! Finance]
2/4
08:10 am
gmab
Biospecimen Management Consortium Accelerates Growth, Releases Landmark Industry Survey, and Launches Key Initiatives [Yahoo! Finance]
Low
Report
Biospecimen Management Consortium Accelerates Growth, Releases Landmark Industry Survey, and Launches Key Initiatives [Yahoo! Finance]
1/23
08:02 am
gmab
Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Low
Report
Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
1/22
06:23 am
gmab
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024
Medium
Report
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024
1/15
10:13 am
gmab
Are Investors Undervaluing Genmab (GMAB) Right Now? [Yahoo! Finance]
Low
Report
Are Investors Undervaluing Genmab (GMAB) Right Now? [Yahoo! Finance]
1/8
09:21 am
gmab
Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Low
Report
Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
12/25
08:51 am
gmab
Genmab A/S (NASDAQ: GMAB) was upgraded by analysts at Sanford C. Bernstein from a "strong sell" rating to a "hold" rating.
Low
Report
Genmab A/S (NASDAQ: GMAB) was upgraded by analysts at Sanford C. Bernstein from a "strong sell" rating to a "hold" rating.
12/16
01:24 pm
gmab
Antibody Discovery Market Industry Forecast Report 2024-2035, Featuring Ablexis, ChemPartner, Creative Biolabs, GenScript, Genmab, Harbour BioMed, MabSilico, Nona Biosciences, WuXi Biologics and More [Yahoo! Finance]
Low
Report
Antibody Discovery Market Industry Forecast Report 2024-2035, Featuring Ablexis, ChemPartner, Creative Biolabs, GenScript, Genmab, Harbour BioMed, MabSilico, Nona Biosciences, WuXi Biologics and More [Yahoo! Finance]
12/16
07:46 am
gmab
FairJourney Biologics Establishes Scientific Advisory Board [Yahoo! Finance]
Low
Report
FairJourney Biologics Establishes Scientific Advisory Board [Yahoo! Finance]
12/13
03:12 pm
gmab
Genmab A/S: Circling Back On This Complicated Story [Seeking Alpha]
Low
Report
Genmab A/S: Circling Back On This Complicated Story [Seeking Alpha]